January 2023
-
Media ReleaseSandoz receives positive CHMP opinion for citrate-free high concentration formulation of adalimumab biosimilarSandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet…
-
Media ReleaseSandoz announces agreement to acquire leading antifungal agent Mycamine® from Astellas, reinforcing hospital offering and leading Anti-Infectives portfolioSandoz plans to acquire worldwide product rights for Mycamine® (micafungin sodium) from Astellas Acquiring leading global echinocandin, one of three major antifungal classes, will significantly…
November 2022
-
Media ReleaseStudy shows that Sandoz employs Germany’s best graduatesCASE study evaluated data from 660 companies across 10 industries Results show that Germany’s smartest graduates work for biotech companies Sandoz takes first place in biotech and healthcare…
-
Media ReleaseSandoz announces further investment in key manufacturing facility in Austria, to support increased global demand for essential antibioticsEUR 50m planned investment to support increased manufacturing capacity for finished dosage form penicillins, the leading class of antibiotics worldwide New project brings total planned investment…
July 2022
-
Media ReleaseApplications for proposed first-of-a-kind multiple sclerosis biosimilar natalizumab accepted by US FDA and EMASubmission of proposed biosimilar supported by comprehensive package; aims to expand treatment access for people with multiple sclerosis in US and EU Multiple sclerosis (MS) is a chronic…
-
Media ReleaseSandoz Supplemental Biologics License Application accepted by US FDA for biosimilar Hyrimoz® (adalimumab-adaz) high concentration formulation (HCF)Submission supported by comprehensive analytical data package and clinical Phase I pharmacokinetics bridging study Proposed Hyrimoz® HCF would help expand access to medicine for patients with…
-
Media ReleaseNovartis delivers continued strong momentum of key growth brands, progress on strategic initiatives and confirms FY’22 Group guidanceAd hoc announcement pursuant to Art. 53 LR Q2 sales grew +5% cc1 (-1% USD) Innovative Medicines (IM) sales grew +5% cc (-1% USD); strong performance of key growth brands including Entresto (+33%…